Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.
BET bromodomain
Chromatin
DNA methylation
DNA methyltransferase
Epigenetics
Histone acetyltransferase
Histone deacetylase
Histone demethylase
Histone methyltransferase
Prostate cancer
Ten-Eleven Translocation
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
25
11
2020
accepted:
06
03
2021
pubmed:
1
4
2021
medline:
19
2
2022
entrez:
31
3
2021
Statut:
ppublish
Résumé
In addition to genetic alterations, epigenetic alterations play a crucial role during prostate cancer progression. A better understanding of the epigenetic factors that promote prostate cancer progression may lead to the design of rational therapeutic strategies to target prostate cancer more effectively. To systematically review recent literature on the role of epigenetic factors in prostate cancer and highlight key preclinical and translational data with epigenetic therapies. We performed a systemic literature search in PubMed. At the request of the editors, we limited our search to articles published between January 2015 and August 2020 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Clinical trials targeting epigenetic factors were retrieved from clinicaltrials.gov. We retrieved 1451 articles, and 62 were finally selected for review. Twelve additional foundational studies outside this time frame were also included. Findings from both preclinical and clinical studies were reviewed and summarized. We also discuss 12 ongoing clinical studies with epigenetic targeted therapies. Epigenetic mechanisms impact prostate cancer progression. Understanding the role of specific epigenetic factors is critical to determine how we may improve prostate cancer treatment and modulate resistance to standard therapies. Recent preclinical studies and ongoing or completed clinical studies with epigenetic therapies provide a useful roadmap for how to best deploy epigenetic therapies clinically to target prostate cancer. Epigenetics is a process by which gene expression is regulated without changes in the DNA sequence itself. Oftentimes, epigenetic changes influence cellular behavior and contribute to cancer development or progression. Understanding how epigenetic changes occur in prostate cancer is the first step toward therapeutic targeting in patients. Importantly, laboratory-based studies and recently completed and ongoing clinical trials suggest that drugs targeting epigenetic factors are promising. More work is necessary to determine whether this class of drugs will add to our existing treatment arsenal in prostate cancer.
Identifiants
pubmed: 33785255
pii: S0302-2838(21)00176-7
doi: 10.1016/j.eururo.2021.03.005
pmc: PMC8547521
mid: NIHMS1683251
pii:
doi:
Substances chimiques
Biomarkers
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-81Subventions
Organisme : NCI NIH HHS
ID : P50 CA097186
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251245
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA186786
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009357
Pays : United States
Informations de copyright
Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Références
Nat Commun. 2015 Sep 25;6:8219
pubmed: 26404510
Prostate. 2015 Dec;75(16):1941-50
pubmed: 26383847
Cell Res. 2011 Mar;21(3):381-95
pubmed: 21321607
Sci Rep. 2019 Mar 7;9(1):3823
pubmed: 30846826
Oncogene. 2017 Apr;36(15):2172-2183
pubmed: 27819678
Cell Rep. 2017 Jun 6;19(10):2045-2059
pubmed: 28591577
Cancer Cell. 2020 Apr 13;37(4):584-598.e11
pubmed: 32220301
Nucleic Acids Res. 2019 Dec 16;47(22):11623-11636
pubmed: 31647098
Chem Biol. 2015 Sep 17;22(9):1185-96
pubmed: 26364928
Cancer Cell. 2019 Apr 15;35(4):603-617.e8
pubmed: 30930119
Eur Urol Oncol. 2021 Jun;4(3):437-446
pubmed: 31402217
Cancer Res. 2016 May 1;76(9):2637-51
pubmed: 26984757
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12315-12323
pubmed: 32424106
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Cell Rep. 2018 Dec 4;25(10):2808-2820.e4
pubmed: 30517868
Clin Cancer Res. 2018 Jul 15;24(14):3317-3324
pubmed: 29615462
Nat Med. 2019 Oct;25(10):1615-1626
pubmed: 31591588
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
BMC Cancer. 2017 Apr 17;17(1):273
pubmed: 28412973
Cancer Res. 2018 Oct 15;78(20):5731-5740
pubmed: 30135193
Clin Epigenetics. 2018 Aug 7;10(1):105
pubmed: 30086793
Oncogene. 2019 Jan;38(1):17-32
pubmed: 30072740
Mol Cancer. 2012 Aug 06;11:52
pubmed: 22867098
Science. 2017 Jan 6;355(6320):78-83
pubmed: 28059767
Neoplasia. 2020 Jun;22(6):253-262
pubmed: 32403054
Prostate. 2019 Oct;79(14):1705-1714
pubmed: 31433512
Cancer Discov. 2018 Jan;8(1):24-36
pubmed: 29263030
Clin Cancer Res. 2019 Dec 1;25(23):6916-6924
pubmed: 31363002
Nat Med. 2017 Sep;23(9):1063-1071
pubmed: 28805820
J Clin Invest. 2020 Apr 1;130(4):1991-2000
pubmed: 32149736
Cancer Cell. 2016 Oct 10;30(4):563-577
pubmed: 27728805
Elife. 2017 Sep 11;6:
pubmed: 28891793
Nat Rev Mol Cell Biol. 2007 Apr;8(4):284-95
pubmed: 17380162
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9
pubmed: 27274052
Commun Biol. 2018 Dec 5;1:217
pubmed: 30534609
Clin Cancer Res. 2019 Jan 1;25(1):52-63
pubmed: 30224345
J Urol. 2014 Oct;192(4):1081-7
pubmed: 24747657
Oncogene. 2016 Jul 21;35(29):3781-95
pubmed: 26640144
Biol Cell. 2011 Aug;103(8):381-401
pubmed: 21736555
Cancer Res. 2008 Jun 1;68(11):4447-54
pubmed: 18519708
Clin Cancer Res. 2020 Oct 15;26(20):5338-5347
pubmed: 32694156
Proc Natl Acad Sci U S A. 2016 May 31;113(22):6259-64
pubmed: 27185910
Nat Genet. 2020 Aug;52(8):778-789
pubmed: 32661416
Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188
pubmed: 29581250
Cancer Cell. 2018 Dec 10;34(6):996-1011.e8
pubmed: 30537516
J Clin Oncol. 2018 Oct 20;36(30):3007-3014
pubmed: 29733771
Nature. 2002 Oct 10;419(6907):624-9
pubmed: 12374981
Clin Cancer Res. 2018 Jul 1;24(13):3149-3162
pubmed: 29555663
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Invest New Drugs. 2015 Aug;33(4):969-76
pubmed: 25983041
Clin Cancer Res. 2019 Nov 1;25(21):6309-6319
pubmed: 31420359
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Nature. 2020 Feb;578(7794):306-310
pubmed: 31969702
Nat Genet. 2020 Aug;52(8):790-799
pubmed: 32690948
Nat Genet. 2020 Oct;52(10):1011-1017
pubmed: 32868907
Genes Dev. 2016 Apr 1;30(7):733-50
pubmed: 27036965
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
J Clin Invest. 2020 Apr 1;130(4):1653-1668
pubmed: 32091413
Nature. 2017 Oct 5;550(7674):128-132
pubmed: 28953875
Nature. 2014 Jun 12;510(7504):278-82
pubmed: 24759320
Oncogene. 2019 Jul;38(28):5658-5669
pubmed: 30996246
Cancer Discov. 2021 May;11(5):1118-1137
pubmed: 33431496
Oncogene. 2020 May;39(19):3939-3951
pubmed: 32203167
Oncogene. 2020 Mar;39(10):2187-2201
pubmed: 31822799
Cancer Res. 2017 Oct 15;77(20):5479-5490
pubmed: 28916652
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Nat Commun. 2020 Nov 3;11(1):5549
pubmed: 33144576
Mol Cancer Res. 2016 Apr;14(4):324-31
pubmed: 26792867
Nat Commun. 2018 Nov 21;9(1):4900
pubmed: 30464211
Nat Med. 2017 Sep;23(9):1055-1062
pubmed: 28805822
Oncogene. 2016 May 12;35(19):2441-52
pubmed: 26279298
Clin Genitourin Cancer. 2015 Feb;13(1):22-31
pubmed: 25178642
Cell Rep. 2018 Jan 16;22(3):796-808
pubmed: 29346775